DISACCHARIDE DERIVATIVES

Abstract: Disaccharide compounds represented by formula (I): wherein R, R¹, R², R³, R⁴, and R⁵ are as defined in the specification and salts thereof are disclosed. The com­ pounds exhibit excellent antitumor activity and low toxicity and are useful as antitumor agents.

Description: This invention relates to novel disaccharide derivatives and salts thereof which exhibit excellent antitumor activity and low toxicity, and are useful as antitumor agents. Natural lipid A has mitogenic activity, i.e., an activity to stimulate lymphocytes to cause blast transformation, which accelerates increase of lymphatic cells thereby to enhance immunity, an activity to derive a tumor necrosis factor, and the like, and is, therefore, promising as treating and prophylactic agent for many diseases caused by reduction of immune function, such as various infectious diseases, or antitumor agents. Known derivatives of natural lipid A include those described in Japanese Patent Application (OPI) Nos. 48497/84, 53295/86, and 227586/86 (the term "OPI" as used herein means "unexamined published Japanese patent application"). Among them, 2-deoxy-6-O-(2-deoxy-2-[(R)3-dodecanoyloxytetradecanoylamino]-4-O-phosphono-3-O-[(R)-4-tetradecanoyloxytetradecanoyl]-β-D-glucopyranosyl)-3-O-[(R)-3-hydroxytetradecanoy]-2-[(R)-3-hydroxytetradecanoylamino]-1-O-phospnono-α-D-glucopyranose disclosed in Japanese Patent Application (OPI) No. 53295/86 (hereinafter referred to as Compound A) is known to have physiological activities equal to or even higher than natural lipid A as reported in Eur. J. Biochem. , Vol. 148, 1-5 (1985). Compound A, however, is of low practical use due to high toxicity similar to natural lipid A. Japanese Patent Application (OPI) 227586/86 (Chemical Abstracts, Vol. 106, 67627k, 1987) discloses disaccharid lipid A analogues of the formula: wherein COCH₂CHR³(CH₂) m Me; R² = COCH₂CHR⁴(CH₂) n Me; m , n = 8-12; R³, R⁴ = H, OH; R⁶, R⁷ = alkanoyl These analogues were shown to have tumor-necrosis factor inducing activity in mice. In Infection and Immunity, 225-237, 1985, S. Kotani, et al, disclose a synthetic compound, β(1-6) D-glucosamine disaccharide 1,4'-bisphosphate, which is acylated at the 2'-amino and 3'hydroxyl groups with (R)-3-dodecanoyloxytetradecanoyl and (R)-3-tetradecanoyloxytetradecanoyl groups, respectively, and has (R)-3-hydroxytetradecanoyl groups at 2-amino and 3-hydroxyl groups. This compound exhibited full endotoxic activities identical to or sometimes stronger than those of a reference lipid A from an Escherichia choli Re-mutant. In Infection and Immunity, 2636-2644, 1987, L. Brade, et al, investigated the immunogenicity and antigenicity of synthetic lipid A and partial structures thereof, among them those compounds which varied in the position of phosphate (1-mono-,4'-mono-, and 1,4'-bisphosphate) and in the acylation (type, number and distribution of fatty acids). It has been keenly demanded to develop compounds exhibiting useful physiological properties with reduced toxicity. This invention relates to compound represented by formula (I): wherein R represents ZR⁶ or wherein Z, Z¹, and Z² each represents an alkylene group having from 1 to 6 carbon atoms, and R⁶ represents a carboxyl group or a phosphonoxy group; R¹, R², R³, and R⁴ each represents -COR⁷, -COZ³R⁸, -CO(CH₂) n2 OCOR⁷, -CO(CH₂) n2 OCOZ³R⁸, -CO(CH₂) n2 COR⁷, -CO(CH₂) n2 COZ³R⁸, wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms which may be substituted with one or more hydroxyl groups, Z³ represents an alkylene group having from 1 to 9 carbon atoms, R⁸ represents a cycloalkyl group having from 3 to 12 carbon atoms which may be substituted with one or more hydroxyl groups, Q represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, -CONH₂, -COOH or -CH₂OH, Q₁ represents a hydrogen atom or an alkyl group having from 1 to 20 carbon atoms, n1 represents 0 or an integer of from 1 to 10, and n2 and n3 each represents an integer of from 1 to 20; and R⁵ represents a hydrogen atom, a phosphono group or -CO(CH₂) m COOH, wherein m represents 0 or an integer of from 1 to 6; and salts thereof. The compounds represented by formula (I) and the salts thereof exhibit excellent antitumor activity and low toxicity and are useful as antitumor agents. The term "alkylene group" as used herein means a methylene group, a polymethylene group, or a methylene or polymethylene group substituted with an alkyl group having from 1 to 6 carbon atoms. Specific examples of the alkylene group are methylene, ethylene, propylene, trimethylene, ethylethylene, tetramethylene, 2-methyltetramethylene, 2,3-dimethyltetramethylene, 2-ethyl-3-methylpentamethylene and octamethylene groups, etc. In formula (I), the alkylene group as represented by Z, Z¹, Z² or Z³ preferably contains from 1 to 4 carbon atoms. The term "alkyl group" as used herein means a straight or branched chain alkyl group and includes, for example, methyl, ethyl, propyl, t-butyl, hexyl, nonyl, decyl, 3-ethylundecyl, 2-ethyl-4-methyltridecyl, tetradecyl, nonadecyl, tetraeicosyl, 2-ethyl-5-propyltetraeicosyl, and octaeicosyl groups. The alkyl group as represented by R⁷ preferably contains from 5 to 20 carbon atoms. The term "cycloalkyl group" as used herein include, for example, cyclopropyl, cyclobutyl, cycloheptyl, cyclohexyl, cycloheptyl, cyclodecyl, and cyclododecyl groups, and preferably those having from 5 to 8 carbon atoms. In formula (I), n1 preferably represents 0 or an integer of from 1 to 5, and n2 and n3 each preferably represents an integer of from 1 to 6. The compounds of formula (I) include α- and β-isomers due to the substituent OR, both of which and a mixture of which fall within the scope of the present invention. Further, the compounds of formula (I) embrace optical isomers and such optical isomers and mixtures thereof also fall within the scope of the present invention. The salts of the compounds of formula (I) include salts formed between the phosphono group or carboxyl group thereof and organic amines, e.g., triethylamine, pyridine, N-methylamine, N-methylglucamine, etc., or inorganic bases, e.g., ammonia or sodium, potassium, calcium, magnesium hydroxide etc. Of the compounds of formula (I), preferred are those wherein R represents ZR⁶ or R¹, R², R³, and R⁴ each represents -COR⁷, -COZ³R⁸, -CO(CH₂) n2 COR⁷ or -CO(CH₂) n2 COZ³R⁸. More preferred are those wherein R represents ZOPO(OH)₂, and R¹, R², R³, and R⁴ each represents -COR⁷ or Further preferred compounds are those, wherein R represents ZR⁶ wherein Z represents a methylene or an ethylene group and R⁶ represents a carboxyl group or a phosphonoxy group R¹ and R³ each represents -COR⁷ wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms R² and R⁴ each represent wherein n1 represents 0 (zero), Q and Q₁ each represent a hydrogen atom and R⁷ represents an alkyl group having from 1 to 30 carbon atoms or -COR⁷ wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms, and R⁵ represents a hydrogen atom. The compounds according to the present invention can be prepared through various reaction routes. One example of the processes is illustrated below. wherein R⁹ represents a hydrogen atom or a hydroxyl-protective group (i.e., a protective group for the hydroxyl group) which can be removed by catalytic reduction or the like; R¹⁰ represents ZCOOR¹⁴, ZOPO(OR¹³)₂, or R¹¹, R²¹ and R³¹ each represents -COR⁷¹, -COZ³R⁸¹, -CO(CH₂) n2 OCOR⁷¹, -CO(CH₂) n2 OCOZ³R⁸¹, -CO(CH₂) n2 COR⁷¹, -CO(CH₂) n2 COZ³R⁸¹, R⁵¹ represents a hydrogen atom, -CO(CH₂) m COOR¹⁶ or PO(OR¹⁵)₂, wherein R¹² and R¹³ each represents a phosphono-protective group which can be removed by catalytic reduction; R¹⁴ represents a carboxyl-protective group which can be removed by catalytic reduction; R⁷¹ represents an alkyl group having from 1 to 30 carbon atoms which may be substituted with one or more hydroxyl groups protected with a hydroxyl-protective group; R⁸¹ represents a cycloalkyl group having from 3 to 12 carbon atoms which may be substituted with one or more hydroxyl groups protected with a hydroxyl-protective group; Q₂ represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, -CONH₂, -COOR¹⁶ or -CH₂-O-R⁹¹, wherein R¹⁶ represents a carboxyl-protective group which can be removed by catalytic reduction; R¹⁵ represents a phosphono-protective group which can be removed by catalytic reduction; and R⁹¹ represents a hydroxyl-protective group which can be removed by catalytic reduction; and Z, Z¹, Z², Z³, Q₁, n1, n2, n3, and m are as defined above. The carboxyl-protective group which can be removed by catalytic reduction includes a benzyl group, etc., which may be substituted with a halogen atom, a nitro group, a lower alkoxy group, etc. The phosphono-protective group which can be removed by catalytic reduction includes a phenyl group, a benzyl group, etc., each of which may be substituted with a halogen atom, a nitro group, a lower alkoxy group, etc. The hydroxyl-protective group includes those removable by catalytic reduction, such as a benzyl group, etc., which may be substituted with a halogen atom, a nitro group, a lower alkoxy group, etc., a trichloroethoxycarbonyl group, a trichloro-t-butoxycarbonyl group, etc. According to the above-described process, the compound of formula (II) is catalytically reduced in an inert solvent, e.g., tetrahydrofuran, methanol, ethanol, acetic acid, water, a mixture of these solvents, etc., in a hydrogen gas atmosphere in the presence of a catalyst, such as palladium black, palladium-on-carbon, platinum dioxide, etc., to thereby remove the protective groups. If desired, the product may be purified by silica gel chromatography or the like technique. The reduction reaction can usually be carried out at a temperature of from room temperature (0 to 30°C) to 60°C for a period of from 1 to 12 hours. The amounts of the solvent and catalyst to be used are not particularly limited. In cases of using the compound of formula (II) wherein R¹¹, R²¹ or R³¹ contains therein a hydroxyl-protective group, such a protective group is preferably the one removable by catalytic reduction. The salt of the compound of formula (I) can be obtained by adding a necessary amount of a base to the compound, followed by sedimentation, freeze-drying or the like means. The process for preparing the starting compound represented by formula (II) can be selected appropriately depending on the kind of the substituents R¹⁰ and R⁵¹ as illustrated below. wherein R¹⁸ represents an allyl group, ZCOOR¹⁴, ZOPO(OR¹³)₂, R¹⁷ represents a hydroxyl-protective group; R⁴¹ represents -COR⁷¹, -COZ³R⁸¹, -CO(CH₂) n2 OCOR⁷¹, -CO(CH₂) n2 OCOZ³R⁸¹, -CO(CH₂) n2 COR⁷¹, -CO(CH₂) n2 COZ³R⁸¹, or R¹⁹ represents ZCOOR¹⁴, ZOPO(OR¹³)₂, R²⁰ represents -CO(CH₂) COOR¹⁶ or PO(OR¹⁵)₂; R⁹² represents a hydroxyl-protective group removable by catalytic reduction; and R¹¹, R²¹, R³¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R⁷¹, R⁸¹, Z, Z¹, Z², Z³, n1, Q₂, Q₁, n2, n3, and m are as defined above. More specifically, the compound of formula (IV) is dissolved in an inert solvent (e.g., methylene chloride, acetic acid, etc., either alone or combinations thereof) containing hydrogen bromide gas and allowed to react at 0°C to room temperature for several tens minutes to about 24 hours to thereby substitute the acetyl group at the 1-position of the sugar moiety by a bromine atom. The resulting bromo-substituted compound is dissolved in a dried solvent, preferably, methylene chloride, chloroform, etc., and then condensed with the compound of formula (III) in the presence of either one or more of mercury (II) cyanide, mercury bromide, silver carbonate, silver oxide, silver perchlorate, mercury (II) nitrate, etc. and in the presence of a dehydrating agent, e.g., anhydrous calcium sulfate, etc., at a temperature of from room temperature to the reflux temperature for a period of several hours to 2 days, thereby to obtain the compound of formula (V). The resulting compound was then reacted with a compound of formula X-R²⁰, wherein X represents a halogen atom, in an organic solvent, e.g., methylene chloride, chloroform, acetonitrile, tetrahydrofuran, etc., in the presence of an organic base, e.g., pyridine, 4-dimethylaminopyridine, triethylamine, etc., or reacted with a compound of formula HO-R²⁰ and a catalyst such as dicyclohexylcarbodiimide in the presence of 4-dimethylaminopyridine to obtain the compound of formula (V'). The compounds represented by formula (IIA) to (IID), i.e., the starting compounds of formula (II), can then be synthesized from the thus obtained compounds of formula (V) and (V') through the following reaction routes (A) to (D). Reaction Route (A) : A compound of formula (V) wherein R¹⁸ = R¹⁹ is dissolved or suspended in acetic acid, and a zinc powder is added thereto to effect reaction thereby removing the amino-protective group at the 2'-position and R¹⁷. The resulting compound freed from the protective group is then condensed with the compound of formula R³¹-OH according to a process commonly employed in peptide synthesis to prepare the compound of formula (IIA). The removal of the protective group is usually performed at room temperature for several tens minutes to 24 hours. The condensation reaction can be effected by a carbodiimide method, the Eintopf method, an active ester method, and the like. In the above-described reaction for removal of protective groups, a trichloroethoxycarbonyl group or a trichloro-t-butoxycarbonyl group is preferred as R¹⁷, i.e., a protective group for a hydroxyl group. When R⁴¹ has a hydroxyl-protective group in the molecule thereof, the same groups are preferred as the hydroxyl-protective group. Reaction Route (B): A compound of formula (V) wherein R¹⁸ is an allyl group is treated in the same manner as in Reaction Route (A) to remove R¹⁷ and then to bond R³¹ to the 2'-positioned amino group. After protecting the 6'-positioned hydroxyl group with a protective group removable by catalytic reduction, the compound is reacted with an iridium complex, e.g., 1,5-cyclooctadienebis(methyldiphenylphosphine)-iridium hexafluorophosphate, etc., followed by hydrolysis to remove the allyl group. The resulting compound is then reacted with to obtain the compound of formula (IIB). Protection of the 6'-positioned hydroxyl group can be carried out, for example, by reacting with benzyloxymethyl chloride in an organic solvent, e.g., anhydrous chloroform, anhydrous methylene chloride, etc., in the presence of an organic base, e.g., pyridine, diisopropylethylamine, etc., at room temperature for 1 to 2 days. The protection may also be effected by using benzyl trichloroacetimidate in the presence of trifluoromethanesulfonic acid at around 0°C. Removal of the allyl group is usually carried out by reacting with the above-described iridium complex in an organic solvent, e.g., methylene chloride, chloroform, tetrahydrofuran, etc., at about 50°C for a period of from 10 minutes to 3 hours and then adding water and iodine to the reaction mixture to effect hydrolysis at room temperature for about 5 to 30 minutes. The reaction between the allyl-free compound and is usually conducted in an anhydrous aprotic solvent, e.g., anhydrous tetrahydrofuran, in the presence of butyl lithium at a temperature of from -70°C to 50°C for several tens minutes. Reaction Route (C): The compound of formula (IIC) can be prepared by subjecting a compound of formula (V') to the same reactions of Reaction Route (A). Reaction Route (D): The compound of formula (IID) can be prepared by subjecting the compound of formula (V') to the same reactions of Reaction Route (B). The compound of formula (IV) used as starting material in the above-illustrated process can be synthesized according to known processes or the process disclosed in Japanese Patent Application (OPI) No. 53295/86. The compound of formula (III), the other starting material in the process, can be prepared by Reaction Route (a) or (b) shown below, selected according to the kind of the substituent R¹⁸. wherein X represents a halogen atom; Y represents a lower acyl group, a trichloroethoxycarbonyl group or a trichloro-t-butoxycarbonyl group; W represents ZOW², ZCOOW², W¹ represents ZOW⁴, ZCOOR¹³, R²² represents ZOPO(OR¹³)₂, ZCOOR¹⁴, W⁶ represents ZOH or W⁷ represents ZOPO(OR¹³)₂ or Y¹ represents a trichloroethoxycarbonyl group or a trichloro-t-butoxycarbonyl group; W² represents an acetyl group, a benzoyl group, a benzyl group or a p-chlorobenzyl group; W³ represents an alkyl group having from 1 to 6 carbon atoms or a carboxyl-protective group removable by catalytic reduction; W⁴ represents a hydrogen atom, a benzyl group or a p-chlorobenzyl group; and R¹¹, R²¹, R¹³, R¹⁴, Z, Z¹, and Z² are as defined above. The compound of formula (VII) can be prepared by reacting a compound of formula (VIa) with a compound of formula WOH in the presence of a Lewis acid or condensing a compound of formula (VIb) with the compound WOH in the presence of mercury (II) cyanide, silver carbonate, mercury bromide, silver perchlorate or mercury (II) nitrate, or a mixture thereof. The compound of formula (VII) wherein W is a ZO-acetyl group can be obtained by reacting a compound of formula (VIc) with a compound of formula HOZOH in the presence of hydrogen chloride, p-toluenesulfonic acid, etc., followed by acetylation. The compound of formula (VII) wherein Y is a lower acyl group is treated with a Meerwein reagent, or the compound of formula (VII) wherein Y is a trichloroethoxycarbonyl or trichloro-t-butoxycarbonyl group is treated with a zinc powder in the presence of hydrochloric acid, acetic acid, etc. to thereby remove the protective group for the 2-positioned amino group. The resulting compound is then condensed with a compound of formula R¹¹OH according to an acid chloride method, a carbodiimide method, the Eintopf method or an active ester method to prepare the compound of formula (VIII). The compound of formula (VIII) wherein W is ZCOO-alkyl or is hydrolyzed with sodium hydroxide, etc. to remove the acyl and alkyl groups, and the resulting compound is reacted with a compound of formula X-R¹⁴ in the presence of an organic amine, e.g., triethylamine, to prepare the compound of formula (IX). The compound of formula (VIII) wherein W has other meaning is hydrolyzed with aqueous ammonia, etc., to obtain the compound of formula (IX). The hydroxyl groups at the 4- and 6-positions of the compound of formula (IX) are protected using isopropylidene to obtain the compound of formula (X). The compound of formula (X) wherein W¹ is a Z-O-benzyl or ZO-p-chlorobenzyl group is condensed with a compound of formula R²¹-OH and then the resulting compound is catalytically reduced to the compound wherein W¹ is ZOH. The resulting compound is reacted with a compound of formula X-PO(OR¹³)₂ in the presence of an organic amine, e.g., triethylamine, 4-dimethylaminopyridine, pyridine, etc. to prepare the compound of formula (XI). The compound of formula (X) wherein W¹ is ZCOOR¹⁴ or is condensed with the compound of formula R²¹-OH to prepare the compound of formula (XI). The compound of formula (IIIa) can be obtained by hydrolyzing the thus prepared compound of formula (XI) in water-containing acetic acid, e.g., a 50 to 90% by weight aqueous solution of acetic acid, or treating the compound with p-toluenesulfonic acid in methanol, ethanol, water or a mixture thereof. The compound of formula (IIIa) wherein R²² is ZOPO(OR¹³)₂ or i.e., the compound of formula (IIIa') can be prepared as follows. The compound of formula (VII) wherein W is ZO-acetyl, ZO-benzoyl, and Y is a trichloroethoxycarbonyl or trichloro-t-butoxycarbonyl group is treated with aqueous ammonia to obtain the compound of formula (XII), which is then protected with isopropylidene to obtain the compound of formula (XIII). The resulting compound is condensed with the compound of formula XPO(OR¹³)₂ and then with the compound of formula R²¹OH to prepare the compound of formula (XIV). The isopropylidene is removed from the resulting compound in the same manner as described above to prepare the compound of formula (XVa). Y¹ of the compound of formula (XVa) is removed in the same manner as described above, and the resulting compound is then condensed with the compound of formula R¹¹OH to obtain the compound of formula (IIIa'). The compound of formula (XVb) can be prepared by removing Y¹ from the compound of formula (XIV) in the same manner as described above and then condensing the resulting compound with the compound of formula R¹¹OH. The isopropylidene is then removed therefrom in the same manner as described above to prepare the compound of formula (IIIa'). The compound of formula (IIIa') wherein R¹¹ and R²¹ are the same can also be obtained by removing Y¹ from the compound of formula (XIII) and condensing the resulting compound with a fatty acid, followed by removing the isopropylidene. Reaction Route (b) : wherein Y¹, R²¹, and R¹¹ are as defined above. The compound of formula (XVI) is condensed with the compound of formula R²¹OH to prepare the compound of formula (XVII). After Y¹ is removed in the same manner as described above, the compound is condensed with the compound of formula R¹¹OH to obtain the compound of formula (XVIII). The isopropylidene is then removed from the compound of formula (XVIII) in the same manner as described above to obtain the compound of formula (IIIb). The compounds according to the present invention exhibit antitumor activity equal to or even higher than that of Compound A and have remarkably lower toxicity as compared with Compound A. Therefore, the compounds of the invention are superior as antitumor agents. The invention also relates to pharmaceutical compositions comprising at least one compound of the invention, optionally together with conventional pharmaceutically acceptable carriers and/or adjuvants. The present invention is now illustrated in greater detail with reference to Reference Examples, Examples, and Test Examples, but it should be understood that the present invention is not construed to be limited thereto. In these examples, all the percents are by weight unless otherwise indicated. REFERENCE EXAMPLE 1 1) Preparation of 2-acetoxyethyl 3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside To 5.00 g of 2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-D-glucose was added 5.0 ml of ethylene glycol and 0.5 ml of dioxane containing hydrogen chloride gas, and the mixture was stirred for 4 hours under heating to 90°C. After cooling with ice-water, 75 ml of pyridine and then 30.6 g of acetic anhydride were added to the reaction mixture, followed by stirring. After 20 minutes' stirring, the reaction mixture was warmed to room temperature, and the stirring was continued for an additional 16 hours. The reaction mixture was poured into 350 ml of ice-water and stirred. The precipitated solid was collected by filtration and washed with water. The resulting solid was dissolved in chloroform, washed successively with 1N hydrochloric acid and a saturated sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was recrystallized from ethanol to obtain 4.96 g of the entitled compound as a colorless prism. Melting Point: 138 - 140°C [α] 25 / D : +74.0° (c=1.2, chloroform) 2) Preparation of 2-acetoxyethyl 3,4,6-tri-O-acetyl-2-deoxy-2-tetradecanoylamino-α-D-glucopyranoside In 60 ml of acetic acid was dissolved 4.96 g of the compound obtained in 1) above, and 7 g of a zinc powder was added thereto in small portions at room temperature while stirring. The stirring was continued for 1 hour, and any insoluble matter was removed by filtration. The solvent was removed from the filtrate by distillation under reduced pressure, toluene was added to the residue, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in dioxane, and dioxane containing hydrogen chloride gas was added to the solution. The solvent was removed by distillation under reduced pressure, and the residue was dried. The resulting oily product was dissolved in 70 ml of anhydrous methylene chloride, and 2.88 ml of N-methylmorpholine and 3.24 g of tetradecanoyl chloride were added to the solution under ice-cooling, followed by stirring for 1 hour. To the reaction mixture was added 10 ml of methanol. After stirring at room temperature for 10 minutes, the reaction mixture was diluted with chloroform, washed successively with 1N hydrochloric acid and a saturated sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography using, as eluent, a mixture of benzene and ethyl acetate at a ratio of 9/1 (v/v) and then 1/1 (v/v) to obtain 4.77 g of the entitled compound as a colorless oily product. 3) Preparation of 2-hydroxyethyl 2-deoxy-2-tetradecanoylamino-α-D-glucopyranoside In 80 ml of absolute methanol was dissovled 4.77 g of the compound obtained in 2) above, and a methanol solution containing 9 mmol of sodium methylate was added to the solution under ice-cooling, followed by stirring at room temperature for 30 minutes. Tetrahydrofuran was added thereto to dissolve the precipitate, the solution was neutralized with a strongly acidic ion exchange resin, Dowex-50 (H⁺ type), and the resin was filtered off. The solvent was removed from the filtrate by distillation under reduced pressure. The residue was washed with diethyl ether, followed by filtration to give 3.02 g of the entitled compound as a white solid. Recrystallization from ethanol-water gave a purified product having a melting point of 158 to 160°C. [α] 25 / D : +8.21° [c=0.8, tetrahydrofuran:water = 4:1 (v/v)] 4) Preparation of 2-hydroxyethyl 2-deoxy-4,6-O-isopropylidene-2-tetradecanoylamino-α-D-glucopyranoside In 20 ml of dimethylformamide was dissolved 0.87 g of the compound obtained in 3) above, and 0.62 g of 2,2-dimethoxypropane and 38 mg of p-toluenesulfonic acid monohydrate were added to the solution at room temperature, followed by stirring for 1.5 hours. After neutralizing with a 5% aqueous solution of sodium hydrogencarbonate, the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate, washed successively with water and a saturated sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using, as eluent, a 19/1 (v/v) mixture of chloroform and acetone and then a 19/1 (v/v) mixture of chloroform and methanol to obtain 0.78 g of the entitled compound as a colorless and viscous oily product. 5) Preporation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-4,6-O-isopropylidene-2-tetradecanoylamino-α-glucopyranoside In 15 ml of anhydrous methylene chloride was dissolved 0.77 g of the compound obtained in 4) above, and to the solution were added 0.48 g of diphenyl phosphorochloridate, 0.19 ml of pyridine, and 0.30 g of dimethylaminopyridine under ice-cooling. After stirring for 1 hour, the temperature of the mixture was returned to room temperature, and the stirring was continued for an additional one hour. To the reaction mixture, 0.17 g of diphenyl phosphorochloridate was added thereto, followed by stirring for 30 minutes. To the reaction mixture was added 3 ml of methanol. After stirring for a while, the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography using a 19/1 (v/v) mixture of chloroform and acetone as an eluent to obtain 0.81 g of the entitled compound as a colorless viscous oil. 6) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside In 5 ml of anhydrous methylene chloride was dissolved 0.51 g of the compound obtained in 5) above, and 0.22 g of N-dodecanoylglycine, 44 mg of dimethylaminopyrdine, and 0.18 g of dicyclohexylcarbadiimide were added to the solution under ice-cooling. The mixture was stirred for 30 minutes under ice-cooling and then at room temperature for 2 hours. The insoluble matter was removed by filtration, and the filtrate was washed successively with 1N hydrochloric acid, water, and a saturated sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and to the residue was added 20 ml of a 90% acetic acid aqueous solution, followed by stirring for 30 minutes while heating at 90°C. The solvent was distilled off, and toluene was added to the residue, followed by distillation to remove the solvent. Addition of toluene and subsequent distillation were repeated once more. The residue was purified by silica gel column chromatography using, as eluent, a 19:1 (v/v) mixture of chloroform and acetone and then a 19:1 (v/v) mixture of chloroform and methanol to obtain 0.51 g of the entitled compound as a colorless oily product. [α] 25 / D : +46.2° (c=1.1, chloroform) NMR (CDCl₃), δ(ppm): 0.88 (6H, t), 1.26 (s), 2.07 (2H, t), 2.27 (2H, t), 4.84 (1H, d), 5.18 (1H, m), 7.2-7.1 (10H, m) REFERENCE EXAMPLE 2 1) Preparation of 2-hydroxyethyl 2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside In 6 ml of a 28% aqueous ammonia and 120 ml of methanol was suspended 5.05 g of the compound prepared in Reference Example 1-1), and the suspension was stirred at room temperature for 8 hours. The reaction mixture was concentrated under reduced pressure to obtain 3.50 g of the entitled compound as a caramel-like substance. NMR (CDCl₃-CD₃OD, ca. 1:1), δ (ppm): 4.78 (2H, s), 4.90 (1H, d) 2) Preparation of 2-hydroxyethyl-2-deoxy-4,6-O-isopropylidene-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside The compound (3.58 g) obtained in 1) above was treated in the same manner as in Reference Example 1-4). To the resulting fraction was added n-hexane, and the precipitated formed was collected by filtration to yield 2.78 g of the entitled compound as a white powder. Melting Point: 190 - 192°C 3) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-4,6-O-isopropylidene-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside The compound (1.12 g) obtained in 2) above was treated in the same manner as in Reference Example 1-5), and to the resulting fraction were added diethyl ether and n-hexane. The precipitate formed was collected by filtration to obtain 1.23 g of the entitled compound. Melting Point: 121 - 124°C [α] 25 / D : +46.4° (c=1.0, chloroform) 4) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-4,6-O-isopropylidene-3-O-tetradecanoyl-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside In 10 ml of anhydrous methylene chloride was dissolved 0.50 g of the compound obtained in 3) above, and 0.30 ml of pyridine, 0.22 g of tetradecanoyl chloride, and 20 ml of dimethylaminopyridine were added to the solution, followed by stirring for 2 hours. To the reaction mixture was added 2 ml of methanol. After stirring at room temperature for a while, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using 2% acetone-containing chloroform and then 5% acetone-containing chloroform as eluent to give 0.49 g of the entiled compound as a colorless oily substance. [α] 25 / D : +36.1° (c=1.0, chloroform) 5) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-2-(N-dodecanoylglycylamino)-4,6-O-isopropylidene-3-O-tetradecanoyl-α-D-glucopyranoside In 12 ml of acetic acid was dissolved 0.47 g of the compound obtained in 4) above, and 0.5 g of a zinc powder was suspended therein, followed by stirring at room temperature for about 1.5 hours. Any insoluble matter was removed by filtration, the filtrate was washed with chloroform, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in chloroform, washed successively with 5% sodium hydrogen carbonate aqueous solution, and a saturated sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was distilled off, and the residual oily substance was dissolved in 8 ml of anhydrous methylene chloride. To the solution was added 0.21 g of N-dodecanoylglycine. To the mixture were added 0.17 g of dicyclohexylcarbodiimide and 32 mg of dimethylaminopyridine under ice-cooling. After 20 minutes, the temperature of the mixture was returned to room temperature, and the mixture was allowed to react for 15 hours while stirring. Any insoluble matter was removed by filtration, and the solvent was removed from the filtrate by distillation under reduced pressure. The residue was purified by silica gel column chromatography using chloroform containing 2 to 10% acetone as eluent. The desired fraction was treated with n-hexane to obtain 0.48 g of the entitled compound as a white powder. Melting Point: 79 - 80°C [α] 25 / D : +28.1° (c=1.1, chloroform) 6) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-2-(N-dodecanoylglycylamino)-3-O-tetradecanoyl-α-D-glucopyranoside In 20 ml of a 90% acetic acid aqueous solution was dissolved 0.45 g of the compound prepared in 5) above, and the solution was stirred for 30 minutes while heating at 90°C. The solvent was removed by distillation under reduced pressure, and toluene was added to the residue, followed by distillation under reduced pressure. Addition of toluene and the subsequent distillation were repeated, and the finally obtained residue was purified by silica gel column chromatography using, as eluent, chloroform containing 5 to 10% acetone and then a 19:1 (v/v) mixture of chloroform and methanol to obtain 0.39 g of the entitled compound as a white waxy solid. [α] 25 / D : +36.1° (c=1.1, chloroform) NMR (CDCl₃), δ(ppm): 0.90 (6H, t), 1.28 (s), 2.13 (2H, m), 2.36 (2H, t), 4.90 (1H, d), 7.2-7.5 (10H, m) REFERENCE EXAMPLE 3 1) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-3-O-(N-dodecanoylglycyl)-4,6-O-isopropylidene-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside In 20 ml of anhydrous methylene chloride was dissolved 1.89 g of the compound obtained in Reference example 2-3), and 0.83 g of N-dodecanoylglycine, 0.17 g of dimethylaminopyridine, and 0.67 g of dicyclohexylcarbodiimide were added thereto- under ice-cooling. After 30 minutes, the mixture was allowed to warm to room temperature and stirred for 1 hour at that temperature. Any insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a 10:1 (v/v) mixture of chloroform and acetone as eluent to obtain 2.80 g of the entitled compound as a colorless oily substance. [α] 25 / D : +32.2° (c=0.8, chloroform) 2) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-3-O-(N-dodecanoylglycyl)-2-[6-(octanoylamino)hexanoylamino]-α-D-glucopyranoside In 10 ml of acetic acid was dissolved 0.71 g of the compound obtained in 1) above, and 0.5 g of a zinc powder was added thereto at room temperature while stirring. After stirring for 2 hours, the insoluble matter was removed by filtration, the filtrate was washed with chloroform, and the solvent was distilled off. The residue was dissolved in chloroform, washed successively with a 5% sodium hydrogencarbonate aqueous solution and a saturated sodium chloride aqueous solution, and dried over anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure to obtain an oily product. Separately, 0.26 g of 6-(octanoylamino)caproic acid was dissolved in 7 ml of anhydrous tetrahydrofuran, and 0.16 g of 1-hydroxybenzotriazole and 0.21 g of dicyclohexylcarbodiimide were added to the solution under ice-cooling. The liquid temperature was gradually returned to room temperature, and the mixture was stirred for 3 hours. The precipitated insoluble matter was removed by filtration. The filtrate was combined with the above-prepared oily product under ice-cooling, followed by warming up to room temperature, at which the mixture was stirred for 4 hours. The solvent was distilled off, and to the residue was added 20 ml of a 90% acetic acid aqueous solution. The mixture was stirred for 20 minutes under heating at 90°C. The solvent was distilled off, and the residue was purified by silica gel column chromatography using successive eluents of a 10:1 (v/v) mixture of chloroform and acetone, a 20:1 (v/v) mixture of chloroform and methanol, and a 10:1 (v/v) mixture of chloroform and methanol to thereby obtain 0.56 g of the entitled compound as a colorless waxy substance. [α] 25 / D : +31.2° (c=1.1, chloroform) NMR (CDCl₃), δ(ppm): 0.88 (6H, t), 2.0-2.4 (6H, m), 4.85 (1H, d), 7.2-7.4 (10H, m) REFERENCE EXAMPLE 4 Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-3-O-(N-dodecanoyl-N-methylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-α-D-glucopyranoside In 10 ml of acetic acid was dissolved 1.00 g of the compound obtained in Reference Example 2-3), and 0.5 g of a zinc powder was added to thereto at room temperature while stirring. The stirring was continued for an additional 2.5 hours, and the insoluble matter was removed by filtration. The filtrate was washed with chloroform, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in chloroform, washed successively with a 5% aqueous solution of sodium hydrogencarbonate and a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residual oily substance and 1.21 g of N-dodecanoyl-N-methylglycine were dissolved in 10 ml of anhydrous methylene chloride. To the solution were added 90 mg of dimthylaminopyridine and 0.92 g of dicyclohexylcarbodiimide under ice-cooling. After warming to room temperature, the mixture was stirred for 3 hours. The precipitated insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The residual oily substance was purified by silica gel column chromatography successively using a 9:1 (v/v) mixture of chloroform and acetone and a 19:1 (v/v) mixture of chloroform and methanol as eluent to obtain an oily substance. The resulting oily substance was dissolved in 40 ml of a 90% acetic acid aqueous solution, followed by stirring for 30 minutes under heating at 90°C. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using, as eluent, a mixture of chloroform and methanol at a ratio of 50:1 (v/v) and then 20:1 (v/v) to obtain 0.87 g of the entitled compound as an oily product. [α] 25 / D : +34.9° (c=1.0, chloroform) NMR (CDCl₃), δ(ppm): 0.89 (6H, t), 1.28 (s), 2.36 (4H, m), 2.84 and 3.00 (total 3H, each s), 3.13 and 3.15 (total 3H, each s), 4.45 (2H, m), 4.87 (1H, d), 7.2-7.4 (10H, m) REFERENCE EXAMPLE 5 1) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-3-O-tetradecanoyl-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside In 15 ml of anhydrous methylene chloride were dissolved 0.50 g of the compound obtained in Reference Example 2-3) and 0.22 g of tetradecanoic acid, and 0.12 g of dimethylaminopyridine and 0.20 g of dicyclohexylcarbodiimide were added to the solution under ice-cooling. The mixture was warmed to room temperature and stirred for 2 hours. The precipitated insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The residual oily substance was subjected to silica gel column chromatography using a 10:1 (v/v) mixture of chloroform and acetone as eluent to obtain an oily substance. The resulting oily substance was dissolved in 10 ml of a 90% acetic acid aqueous solution, followed by stirring for 25 hours while heating at 90°C. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using, as eluent, a 10:1 (v/v) mixture of chloroform and acetone and then a 10:1 (v/v) mixture of chloroform and methanol to obtain 0.61 g of an oily product. [α] 25 / D : +43.0° (c=1.2, chloroform) 2) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-2-[(N-dodecanoyl-D-isoglutaminyl)amino]-3-O-tetradecanoyl-α-D-glucopyranoside The compound (0.47 g) obtained in 1) above was treated with a zinc powder in an acetic acid solution and then reacted with N-dodecanoyl-D-isoglutamine in the same manner as in Reference Example 3-2) to obtain 0.36 g of the entitled compound as a white waxy substance. [α] 25 / D : +38.7° (c=0.1, chloroform) NMR (CDCl₃), δ(ppm): 0.88 (6H, t), 1.26 (s), 2.1-2.5 (6H, m), 4.96 (1H, d), 5.18 (1H, d), 7.2-7.5 (10H, m) REFERENCE EXAMPLE 6 1) Preparation of 1,3-(diethoxycarbonyl)isopropyl 2-deoxy-3,4,6-tri-O-acetyl-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside To 8.00 g of 1,3,4,6-tetra-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-D-glucopyranose was added a cooled acetic acid solution containing 25% hydrogen bromide at room temperature, followed by stirring for 1 hour. The reaction mixture was diluted with chloroform, washed successively with a 5% sodium hydrogencarbonate aqueous solution and a saturated sodium chloride aqueous solution, and dried over anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was dissolved in 72 ml of anhydrous methylene chloride. To the solution were added 8 g of anhydrous calcium sulfate, a suspension of 4.12 g of silver perchlorate in 40 ml of anhydrous benzene, and 6.24 g of diethyl-3-hydroxyglutarate under ice-cooling. The mixture was allowed to react at room temperature for 3 hours, followed by neutralizing with a 5% aqueous solution of sodium hydrogencarbonate. The insoluble matter was removed by filtration, and the filtrate was washed with water and dried over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography using 30:1 (v/v) mixture of chloroform and acetone as eluent to obtain 7.36 g of the entitled compound as an oily substance. [α] 25 / D : +42.8° (c=0.7, chloroform). 2) Preparation of 1,3-(diethoxycarbonyl)isopropyl 2-deoxy-2-tetradecanoylamino-3,4,6-tri-O-acetyl-α-D-glucopyranoside The compound (4.00 g) obtained in 1) above was treated with a zinc powder in an acetic acid solution and then reacted with tetradecanoic acid in the same manner as in Reference Example 3-2) to obtain 3.78 g of the entitled compound as an oily substance. [α] 25 / D : +46.9° (c=0.16, chloroform) 3) Preparation of 1,3-(dibenzyloxycarbonyl)isopropyl 2-deoxy-2-tetradecanoylamino-α-D-glucopyranoside In 30 ml of dioxane was dissolved 1.80 g of the compound obtained in 2) above, and 10 ml of water was added thereto. After cooling to 5°C, 15 ml of a 1N potassium hydroxide aqueous solution was added to the solution. After stirring for 6 hours, 1N hydrochloric acid was added thereto to adjust to a pH of 7.5. The reaction mixture was concentrated to dryness under reduced pressure. The residue was suspended in 100 ml of dimethylformamide, and 1 ml of benzyl bromide was added thereto. After stirring at 40°C for 3 hours, most of the dimethylformamide was removed by distillation under reduced pressure. The residue was extracted with benzene, and the benzene layer was washed successively with a 5% citric acid aqueous solution, a saturated sodium chloride aqueous solution, a 5% sodium hydrogencarbonate aqueous solution, and a saturated sodium chloride aqueous solution, and dried over anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using, as eluent, a mixture of chloroform, methanol, and acetone at a volume ratio of 50:1:5 and then 50:1:15 to obtain 0.65 g of the entitled compound as a white waxy solid. [α] 25 / D : +13.2° (c=0.51, chloroform) 4) Preparation of 1,3-(dibenzyloxycarbonyl)isopropyl 2-deoxy-4,6-O-isopropylidene-2-tetradecanoylamino-α-D-glucopyranoside In 10 ml of acetone was dissolved 0.64 g of the compound obtained in 3) above and treated in the same manner as in Reference Example 1-4) to obtain 0.54 g of the entitled compound as an oily substance. [α] 25 / D : +3.3° (c=0.7, chloroform) 5) Preparation of 1,3-(dibenzyloxycarbonyl)isopropyl 2-deoxy-3-O-tetradecanoyl-2-tetradecanoylamino-α-D-glucopyranoside In the same manner as in Reference Example 1-6), 0.48 g of the compound obtained in 4) above was reacted with tetradecanoic acid, and the reaction product was heated in a 90% acetic acid aqueous solution to obtain 0.53 g of the entitled compound as a white waxy solid. [α] 25 / D : +32.8° (c=0.9, methanol NMR (CDCl₃), δ(ppm): 0.88 (6H, t), 1.26 (s), 4.94 (1H), 5.20 (4H, s), 7.40 (10H, s) REFERENCE EXAMPLE 7 Preparation of 1,3-(dibenzyloxycarbonyl)isopropyl 2-deoxy-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside In the same manner as in Reference Example 1-6), 0.60 g of the compound obtained in Reference Example 6-4) was reacted with N-dodecanoylglycine, and the reaction product was treated with a 90% acetic acid aqueous solution to obtain 0.63 g of the entitled compound as a waxy solid. [α] 25 / D : +36.9° (c=1.3, chloroform) NMR (CDCl₃), δ(ppm): 0.89 (6H, t), 1.26 (s), 2.1-2.3 (4H, m), 2.5-2.9 (4H, m), 4.50 (1H, m), 4.97 (1H, d), 5.07 (1H, m), 5.18 (4H), 7.40 (10H, s) REFERENCE EXAMPLE 8 1) Preparation of 2-acetoxyethyl 3,4,6-tri-O-acetyl-2-deoxy-2-[6-(octanoylamino)hexanoylamino]-α-D-glucopyranoside In the same manner as in Reference Example 2-5), 3.00 g of the compound obtained in Reference Example 1-1) was treated with a zinc powder in an acetic acid solution, and the reaction product was reacted with 6-(octanoylamino)caproic acid to obtain 2.84 g of the entitled compound as a waxy solid. [α] 25 / D : +55.4° (c=1.1, chloroform) 2) Preparation of 2-hydroxyethyl 2-deoxy-2-[6-(octanoylamino)hexanoylamino]-α-D-glucopyranoside In the same manner as in Reference Example 1-3), 2.82 g of the compound obtained in 1) above was reacted to yield 1.66 g of the entitled compound as a white powder. Melting Point: 156-157°C [α] 25 / D : +78.8° (c=0.9, ethanol) 3) Preparation of 2-hydroxyethyl 2-deoxy-4,6-O-isopropylidene-2-[6-(octanoylamino)hexanoylamino]-α-D-glucopyranoside In the same manner as in Reference Example 1-4), 1.60 g of the compound prepared in 2) above was reacted to yield 1.48 g of the entitled compound as an oily substance. [α] 25 / D : +35.2° (c=1.0, chloroform) 4) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-4,6-O-isopropylidene-2-[6-(octanoylamino)hexanoylamino]-α-D-glucopyranoside In the same manner as in Reference Example 1-5), 1.26 g of the compound obtained in 3) above was reacted to obtain 1.35 g of the entitled compound as an oily substance. [α] 25 / D : +26.7° (c=1.2, chloroform) 5) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-3-O-dodecanoyl-2-[6-(octanoylamino)hexanoylamino]-α-D-glucopyranoside In the same manner as in Reference Example 1-6), 0.65 g of the compound obtained in 4) above was reacted with dodecanoic acid, and the reaction product was heated in a 90% acetic acid aqueous solution to obtain 0.73 g of the entitled compound as an oily substance. [α] 25 / D : +37.3° (c=1.1, chloroform) NMR (CDCl₃), δ(ppm): 0.89 (6H, m), 2.10 (4H, m), 2.33 (2H, m), 3.20 (2H, m), 4.30 (1H, m), 4.46 (2H, m) 4.85 (1H, d), 5.10(1H, m) REFERENCE EXAMPLE 9 1) Preparation of 2-acetoxyethyl 3,4,6-tri-O-acetyl-2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-α-D-glucopyranoside In the same manner as in Reference Example 2-5), 3.00 g of the compound obtained in Reference Example 1-1) was treated with a zinc powder in an acetic acid solution, and the reaction product was reacted with 1.95 g of (R)-3-benzyloxytetradecanoic acid to yield 3.70 g of the entitled compound as an oily substance. NMR (CDCl₃), δ(ppm): 0.87 (3H, t, J=6Hz), 2.00 (3H, s), 2.02 (3H, s), 2.04 (3H, s), 2.08 (3H, s), 2.18 (2H, m), 4.54 (2H, ABq, J=12Hz), 4.76 (1H, d, J=4Hz), 7.36 (5H, s) 2) Preparation of 2-hydroxyethyl 2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-α-D-glucopyranoside In the same manner as in Reference Example 1-3), 3.68 g of the compound prepared in 1) above was reacted to obtain 2.49 g of the entitled compound as a pale brown powder. Recrystallized from water-ethanol. Melting Point: 125-127°C [α] 25 / D : +73.3° (c=0.9, methanol) 3) Preparation of 2-hydroxyethyl 2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-4,6-O-isopropylidene-α-D-glucopyranoside In the same manner as in Reference Example 1-4), 0.98 g of the entitled compound was obtained as a colorless oily substance from 1.20 g of the compound prepared in 2) above. [α] 25 / D : +31.4° (c=0.9, chloroform) 4) Prepartion of 2-(diphenylphosphonoxy)ethyl 2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-4,6-O-isopropylidene-α-D-glucopyranoside In the same manner as in Reference Example 1-5), 0.98 g of the entitled compound was obtained as a colorless oily substance from 0.83 g of the compound prepared in 3) above. NMR (CDCl₃), δ(ppm): 0.88 (3H, t, J=7Hz), 1.46 (3H, s), 1.53 (3H, s), 2.47 (2H, d, J=6Hz), 4.2 (3H, m), 4.53 (2H, ABq, J=12Hz), 4.64 (1H, d, J=4Hz), 7.2-7.4 (15H, m) 5) Prepartion of 2-(diphenylphosphonoxy)ethyl 3-O-[(R)-3-benzyloxytetradecanoyl)-2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-α-D-glucopyranoside In the same manner as in Reference Example 1-6), 0.96 g of the compound obtained in 4) above was reacted with 0.59 g of (R)-3-benzyloxytetradecanoic acid, and the reaction product was heated with a 90% acetic acid solution to obtain 1.23 g of the entitled compound as a colorless oily substance. [α] 25 / D : +31.4° (c=1.2, chloroform) NMR (CDCl₃), δ(ppm): 0.88 (6H, t, J=7Hz), 2.34 (2H, d, J=6Hz), 2.6 (2H, m), 4.51 (2H, ABq, J=12Hz), 4.56 (2H, s), 4.71 (1H, d, J=4Hz), 5.13 (1H, m), 7.2-7.4 (20H, m) REFERENCE EXAMPLE 10 Preparation of 2-(diphenylphosphonoxy)ethyl 3-O-[(R)-3-benzyloxytetradecanoyl]-2-deoxy-2-tetradecanoylamino-α-D-glucopyranoside In the same manner as in Reference Example 1-6), the compound obtained in Reference Example 1-5) was reacted with (R)-3-benzyloxytetradecanoic acid, and the reaction product was heated in a 90% acetic acid solution to obtain the entitled compound as an oily substance. NMR (CDCl₃), δ(ppm): 0.89 (6H, t), 2.06 (2H, t), 2.1-2.8 (2H, m), 4.85 (1H, d), 5.14 (1H, t), 7.1-7.3 (15H, m) REFERENCE EXAMPLE 11 Preparation of 2-(diphenylphosphonoxy)ethyl 2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-3-O-tetradecanoyl-α-D-glucopyranoside In the same manner as in Reference Example 1-6), the compound prepared in Reference Example 9-4) was reacted with tetradecanoic acid, and the reaction product was heated in a 90% acetic acid aqueous solution to obtain the entitled compound as a colorless oily substance. NMR (CDCl₃), δ(ppm): 0.88 (6H, t), 2.3-2.4 (4H, m), 4.52 (2H, d), 4.72 (1H, d), 5.10 (1H, m), 7.2-7.5 (15H, m) REFERENCE EXAMPLES 12 TO 52 In the same manner as described in Reference Examples 1 to 11, the following compounds represented by formula (IIIa) were prepared. In the same manner as described in Reference Examples 1 to 11, the following compounds represented by formula (IIIb) were prepared. EXAMPLE 1 1) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-6-O-[2-deoxy-4-α-diphenylphosphono-3-O-(N-dodecanoylglycyl)-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-α-D-glucopyranoside In 2 ml of anhydrous methylene chloride was dissolved 370 mg of 1-O-acetyl-2-deoxy-4-α-diphenylphosphono-3-O-(N-dodecanoylglycyl)-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-D-glucopyranose, and 6 ml of a cooled acetic acid solution containing 25% hydrogen bromide was added to the solution at room temperature, followed by stirring for 1 hour. The reaction mixture was diluted with chloroform, washed successively with ice-water, a 5% sodium hydrogencarbonate aqueous solution, and a saturated sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure. The residue and 344 mg of 2-(diphenylphosphonoxy)ethyl 2-deoxy-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-α-D-glucopyranoside were dissolved in 5 ml of anhydrous methylene chloride. To the solution were added 0.5 g of activated calcium sulfate and 182 mg of mercury (II) cyanide, and the mixture was heated to 50 to 60°C and stirred for 3 hours. The insoluble matter was removed by filtration through Celite, and the filtrate was washed successively with a 5% potassium iodide aqueous solution and a saturated sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography using, as eluent, a 10:1 (v/v) mixture of chloroform and acetone, followed by a 50:1 (v/v) mixture of chloroform and methanol, and followed by a 20:1 (v/v) mixture of chloroform and methanol to thereby obtain 599 mg of the entitled compound as an oily substance. [α] 25 / D : +20.0° (c=1.0, chloroform) 2) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-6-O-(2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-β-D-glucopyranoxy)-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-α-D-glucopyranoside In 8 ml of acetic acid was dissolved 587 mg of the compound prepared in 1) above, and 0.6 g of a zinc powder was suspended in the solution, followed by stirring at room temperature for 2 hours. The insoluble matter was removed by filtration, and the filtrate was washed with chloroform. The solvent was removed by distillation under reduced pressure, and toluene was added to the residue, followed by distillation to remove the solvent. Addition of toluene and subsequent distillation were repeated three times in total, and the residue was dissolved in chloroform. The chloroform layer was washed successively with 1N hydrochloric acid, a 5% sodium hydrogencarbonate aqueous solution, and a saturated sodium chloride aqueous solution and dried over anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure to obtain an oily product. Separately, 122 mg of N-dodecanoyl-N-methylglycine was dissolved in 3 ml of anhydrous tetrahydrofuran, and to the solution were added 77 mg of 1-hydroxybenzotriazole and 103 mg of dicyclohexylcarbodiimide, followed by stirring on an ice bath. Thirty minutes later, the liquid temperature was returned to room temperature, and the stirring was continued for an additional 3 hours. The precipitated crystals were removed by filtration. The above prepared oily substance was dissolved in 5 ml of anhydrous methylene chloride, and the filtrate was added thereto under ice-cooling. The temperature of the mixture was returned to room temperature, and the mixture was stirred at that temperature for 1.5 hours. The reaction mixture was diluted with chloroform, washed with 1N hydrochloric acid, dried over anhydrous sodium sulfate, and then distilled to remove the solvent. The residue was purified by silica gel column chromatography using, as eluent, a 10:1 (v/v) mixture of chloroform and acetone, then a 50:1 (v/v) mixture of chloroform and methanol, and finally a 20:1 (v/v) mixture of chloroform and methanol to yield 445 mg of the entitled compound as an oily substance. [α] 25 / D : +19.2° (c=1.0, chloroform) 3) Preparation of 2-phosphonoxyethyl 2-deoxy-6-O-(2-deoxy-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-4-O-phosphono-β-D-glucopyranosyl)-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-α-D-glucopyranoside In a mixture of 50 ml of tetrahydrofuran and 2.5 ml of water was dissolved 424 mg of the compound prepared in2) above, and 0.2 g of platinum dioxide was added thereto, followed by stirring under a hydrogen gas for 2 hours. The catalyst was removed by filtration, and the filter cake was washed with a 8:3:1 (v/v) mixture (lower layer) of chloroform, methanol, and water. The filtrate and the washing were combined, and the solvent was removed therefrom by distillation under reduced pressure. The residue was purified by thin layer chromatography using a 6:4:0.7 (v/v) mixture of chloroform, methanol, and water as developing solvent, and then treated with a strongly acidic ion exchange resin, Dowex 50 (H⁺ type) produced by Dow Chemical Co., Ltd.). The solvent was removed by distillation under reduced pressure, and the residue was suspended in dioxane. Freeze-drying of the suspension gave 204 mg of the entitled compound as a white powder. Melting Point: 165-170°C (gradually colored and turned to jelly) [α] 25 / D : +4.6 [c=0.7, chloroform:methanol=3:l (v/v)] 3400, 2930, 2850, 1750, 1675, 1650 NMR (CDCl₃-CD₃OD), δ(ppm): 0.90 (12H, t), 1.30 (s), 2.29 (4H, m), 2.44 (4H, t), 2.94 and 3.11 (total 6H, each s), 4.84 (1H, d), 5.18 (1H, m), 5.34 (1H, m) A part of the resulting product was dissolved in a 3:1 (v/v) mixture of chloroform and methanol, and the solution was adjusted to a pH of about 9 with triethylamine, followed by concentration under reduced pressure. The residue was dissolved in a 0.1% triethylamine aqueous solution, followed by filtration through a millipore filter. The filtrate was freeze-dried to produce a triethylamine salt of the entitled compound as a white powder. EXAMPLE 2 1) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-6-O-[2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl]-2-[6-(octanoylamino)hexanoylamino]-3-O-tetradecanoyl-α-D-glucopyranoside In the same manner as in Example 1-1), 445 mg of 1-O-acetyl-2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-D-glycopyranose and 385 mg of 2-(diphenylphosphonoxy)ethyl 2-deoxy-2-[6-(octanoylamino)hexanoylamino]-3-O-tetradecanoyl-α-D-glucopyranoside were reacted to obtain 650 mg of the entitled compound as an oily substance. [α] 25 / D : +22.2° (c=1.0, chloroform) 2) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-6-O-[2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-β-D-glucopyranosyl]-2-[6-(octanoylamino)hexanoylamino]-3-O-tetradecanoyl-α-D-glucopyranoside In 10 ml of acetic acid was dissolved 620 mg of the compound prepared in 1) above, and 1.5 g of a zinc powder was suspended therein, followed by stirring at room temperature for 3 hours. Any insoluble matter was removed by filtration, and solvent was removed by distillation under reduced pressure, and the residue was dissolved in chloroform. The solution was washed successively with 1N hydrochloric acid, water, a 5% sodium hydrogencarbonate aqueous solution, and water, and dried over anhydrous magnesium sulfate. The solvent was removed by concentration under reduced pressure, and the residue was dissolved in 10 ml of anhydrous tetrahydrofuran. To the solution were added 98 mg of tetradecanoic acid, 58 mg of 1-hydroxybenzotriazole, and 90 mg of dicyclohexylcarbodiimide under ice-cooling, and the liquid temperature was gradually elevated up to room temperature, followed by stirring for one night. The precipitated insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The residual solid was purified by silica gel column chromatography using, as eluent, a 10:1 (v/v) mixture of chloroform and acetone and then a 30:1 (v/v) mixture of chloroform and methanol, and then powderized from acetonitrile to obtain 428 mg of the entitled compound as a white powder. Melting Point: 105-107°C [α] 25 / D : +24.7° (c=1.0, chloroform) 3) Preparation of 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-β-D-glucopyranosyl]-2-[6-(octanoylamino)hexanoylamino]-3-O-tetradecanoyl-α-D-glucopyranoside In the same manner as in Example 1-3), 350 mg of the compound prepared in 2) above was reacted to obtain 162 mg of the entitled compound as a white powder. Melting Point: 169-172°C (colored and turned to jelly) [α] 25 / D : +19.5° [c=0.6, chloroform:methanol = 3:1 (v/v)] 3405, 2925, 2855, 1740, 1645, 1560, 1460 NMR (CDCl₃), δ(ppm): 0.90 (12H, t), 1.30 (s), 2.1-2.4 (10H, m), 3.19 (2H, t), 5.17 (1H, t), 5.38 (1H, t) The resulting compound was treated in the same manner as in Example 1-3) to obtain a triethylamine salt of the entitled compound as a white powder. EXAMPLE 3 1) Prepartion of 2-(diphenylphosphonoxy)ethyl 2-deoxy-6-O-[2-deoxy-4-O-diphenylphosphono-3-O-(4-oxotetradecanoyl-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl]-3-O-(4-oxotetradecanoyl)-2-tetradecanoylamino-α-D-glucopyranoside In the same manner as in Example 1-1), 435 mg of 1-O-acetyl-2-deoxy-4-O-diphenylphosphono-3-O-(4-oxotetradecanoyl)-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-D-glucopyranose and 380 mg of 2-(diphenylphosphonoxy)ethyl 2-deoxy-3-O-(4-oxotetradecanoyl)-2-tetradecanoylamino-α-D-glucopyranoside were reacted to obtain 516 mg of the entitled compound as an oily substance. [α] 25 / D : +14.7° (c=0.03, chloroform) 2) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-6-O-[2-deoxy-4-O-diphenylphosphono-3-O-(4-oxotetradecanoyl)-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(4-oxotetradecanoyl)-2-tetradecanoylamino-α-D-glucopyranoside In 5 ml of acetic acid was dissolved 510 mg of the compound prepared in 1) above, and 0.5 g of a zinc powder was suspended in the solution, followed by stirring at room temperature for 1.5 hours. The insoluble matter was removed by filtration, and the filtrate was distilled under reduced pressure. The resulting residue was diluted with chloroform, washed successively with 1N hydrochloric acid, a 5% sodium hydrocarboncarbonate aqueous solution, and water, dried over anhydrous sodium sulfate, and distilled under reduced pressure to remove the solvent. The resulting oily substance was dissolved in 2 ml of anhydrous methylene chloride, and to the solution were added 88 mg of tetradecanoyl chloride and 2 ml of N-methylmorpholine under ice-cooling. The mixture was stirred at the same temperature for 30 minutes. The reaction mixture was diluted with chloroform, washed successively with 1N hydrochloric acid and water, and dried over anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using, as eluent, chloroform and then a 20:1 (v/v) mixture of chloroform and methanol to obtain 229 mg of the entitled compound as an oily substance. [α] 25 / D : +17.3° (c=0.2, chloroform) 3) Preparation of 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-(4-oxotetradecanoyl)-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(4-oxotetradecanoyl)-2-tetradecanoylamino-α-D-glucopyranoside In the same manner as in Example 1-3), 225 mg of the compound prepared in 2) above was reacted and treated to obtain 91 mg of the entitled compound as a white powder. Melting Point: 166-170°C (colored and jelly-like) 3406, 2926, 2854, 1710, 1662, 1557, 1470 NMR (CDCl₃-CD₃OD), δ(ppm): 0.88 (12H, t), 1.26 (s), 2.22 (4H, m), 2.54 (4H, t), 2.64 (4H, m), 2.76 (4H, m), 5.16 (1H, t), 5.30 (1H, t) The resulting compound was treated in the same manner as in Example 1-3) to obtain a triethylamine salt thereof as a white powder. EXAMPLE 4 1) Preparation of benzyloxycarbonylmethyl 2-deoxy-6-O-[2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl]-3-O-tetradecanoyl-2-tetradecanoylamino-α-D-glucopyranoside In the same manner as in Example 1-1), 303 mg of 1-O-acetyl-2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoyl glycyl)-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-D-glucopyranose and 217 mg of benzyloxycarbonylmethyl 2-deoxy-3-O-tetradecanoyl-2-tetradecanoylamino-α-D-glucopyranoside were reacted to obtain 408 mg of the entitled compound as an oily substance. [α] 25 / D : +25.8° (c=1.0, chloroform) 2) Preparation of benzyloxycarbonylmethyl 2-deoxy-6-O-[2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-tetradecanoyl-2-tetradecanoylamino-α-D-glucopyranoside In the same manner as in Example 1-2), 389 mg of the compound prepared in 1) above was reacted with tetradecanoic acid to obtain 293 mg of the entitled compound as an oily substance. [α] 25 / D : +28.4° (c=1.1, chloroform) 3) Preparation of carboxymethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-tetradecanoyl-2-tetradecanoylamino-α-D-glucopyranoside In a mixture of 40 ml of tetrahydrofuran and 1 ml of water was dissolved 278 mg of the compound prepared in 2) above, and 0.3 g of 5% palladium-on-carbon was added thereto, followed by stirring under a hydrogen gas for 1 hour. Then, 150 mg of platinum dioxide was added thereto, and the stirring under a hydrogen gas was continued for an additional 2.5 hours. The catalyst was filtered, and the filtrate was distilled to remove the solvent. The residue was purified by thin layer chromatography using, as developing solvent, a lower layer of a 8:3:1 (v/v) mixture of chloroform, methanol, and water and then treated with a strongly acidic ion exchange resin, Dowex 50 (H⁺ type). The active fraction was distilled to remove the solvent, and the residue was suspended in dioxane. The suspension was freeze-dried to obtain 68 mg of the entitled compound as a white powder. Melting point: 150-155°C (colored and jelly-like) 3400, 2925, 2855, 1745, 1650, 1470 NMR (CDCl₃), δ(ppm): 0.90 (12H, t), 1.30 (s), 2.1-2.4 (8H, m), 4.82 (2H, m), 5.22 (1H, t), 5.37 (1H, t) EXAMPLE 5 1) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-6-[2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl]-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-α-D-glucopyranoside In 5 ml of anhydrous methylene chloride was dissolved 500 mg of the compound prepared in Example 1-1), and 0.04 ml of pyridine, 139 mg of diphenylphosphorochloridate. and 64 mg of 4-dimethylaminopyridine were added thereto in this order at room temperature, followed by stirring overnight. The reaction mixture was diluted with methylene chloride, washed successively with a 10% hydrochloric acid aqueous solution, a saturated sodium hydrogencarbonate aqueous solution, and a saturated sodium chloride aqueous solution, and dried over anhydrous magnesium sulfate. The solvent was removed therefrom by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using a 40:1 (v/v) mixture of chloroform and methanol as eluent to obtain 368 mg of the entitled compound as an oily substance. [α] 25 / D : +21.9° (c=0.8, chloroform) 2) Preparation of 2-(diphenylphosphonoxy)ethyl 2-deoxy-6-O-[2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-2-[N-dodecanoyl-N-methylglycyl)amino]-β-D-glucopyranosyl)-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycl)amino]-α-D-glucopyranoside In the same manner as in Example 1-2), 350 mg of the compound obtained in 1) above was treated with a zinc powder in an acetic acid solution and then reacted with N-dodecanoyl-N-methylglycine to obtain 244 mg of the entitled compound as an oily substance. [α] 25 / D : +3.5° (c=0.6, chloroform) 3) Preparation of 2-phosphonoxyethyl 2-deoxy-6-O-(2-deoxy-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-4-O-phosphono-β-glucopyranosyl)-3-O-(N-dodecanoylglycyl)-2-[(N-dodecanoyl-N-methylglycyl)amino]-4-O-phosphono-α-D-glucopyranoside In the same manner as in Example 1-3), 238 mg of the compound prepared in 2) above was subjected to catalytic reduction to obtain 101 mg of the entitled compound as a white powder. Melting Point: 184-189°C (colored and jelly-like) [α] 25 / D : -4.3° [c=0.6, chloroform:methanol = 3:1 (v/v)] 3280, 2900, 1740, 1660, 1640 NMR (CDCl₃-CD₃OD), δ(ppm): 0.89 (12H, t, J=7.0Hz), 1.28 (brs), 1.62 (8H, br), 2.24-2.31 (4H, m), 2.40-2.42 (4H, m), 2.91-2.96, 3.09, 3.12 (total 6H, each s), 4.84 (1H, d), 5.19 (1H, t), 5.31 (1H, t) EXAMPLE 6 1) Preparation of 2-(diphenylphosphonoxy)ethyl 3-O-[(R)-3-benzyloxytetradecanoyl]-2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-6-O-(2-deoxy-4-O-diphenylphosphono-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-3-O-[(R)-3-(2,2,2-trichloroethoxycarbonyloxy)tetradecanoyl]-β-D-glucopyranosyl)-α-D-glucopyranoside In the same manner as in Example 1-1), 409 mg of 1-O-acetyl-2-deoxy-4-O-diphenylphosphono-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-3-O-[(R)-3-(2,2,2-trichloroethoxycarbonyloxy)tetradecanoyl]-D-glucopyranose was reacted with hydrogen bromide to obtain an oily substance, and the resulting oily substance was reacted with 370 mg of 2-(diphenylphosphonoxy)ethyl 3-O-[(R)-3-benzyloxytetradecanoyl]-2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-α-D-glucopyranoside in the presence of mercury (II) cyanide to obtain 577 mg of the entitled compound as a pale yellow, viscous oily substance. [α] 25 / D : +20.2° (c=0.2, chloroform) 2) Preparation of 2-(diphenylphosphonoxy)ethyl 3-O-[(R)-3-benzyloxytetradecanoyl]-2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-6-O-(2-deoxy-4-O-diphenylphosphono-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoylamino]-β-D-glucopyranosyl)-α-D-glucopyranoside In the same manner as in Example 1-2), 555 mg of the compound prepared in 1) above was treated with a zinc powder in an acetic acid solution, and the reaction product was reacted with 93 mg of (R)-3-hydroxytetradecanoic acid to obtain 312 mg of the entitled compound as a colorless oily substance. [α] 25 / D : +6.3° (c=0.7, chloroform) 3) Preparation of 2-phosphonoxyethyl 2-deoxy-6-O-(2-deoxy-3-O-[(R)-3-hydroxyttradecanoyl]-2-[(R)3-hydroxytetradecanoylamino]-4-O-phosphono-β-D-glucopyranosyl)-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoylamino]-α-D-glucopyranoside In the same manner as in Example 4-3), 294 mg of the compound prepared in 2) above was catalytically reduced in the presence of a 5% palladium-on-carbon catalyst to obtain the entitled compound. The compound was treated with a 0.1% triethylamine aqueous solution to obtain 76 mg of a triethylamine salt of the entitled compound as a white powder. A part of the product was treated with a strongly acidic ion exchange resin to obtain the entitled compound in a free form as a white powder. The following data are of the free compound. [α] 25 / D : -1.8° [c=0.5, chloroform:methanol = 3:1 (v/v)] Melting Point: 155-158°C (colored and jelly-like) 3440, 2930, 2860, 1740, 1660 NMR (CDCl₃-CD₃OD), δ(ppm): 0.90 (12H, t), 2.3-2.5 (8H, m), 5.2 (2H, m) EXAMPLE 7 1) Preparation of 2-(diphenylphosphonoxy)ethyl 4-O-[3-(benzyloxycarbonyl)propionyl]-2-deoxy-6-O-[2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside In 6 ml of anhydrous methylene chloride was dissolved 483 mg of 2-(diphenylphosphonoxy)ethyl 2-deoxy-6-O-[2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-6-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside, and 108 mg of monobenzyl succinate and 16 mg of of dimethylaminopyridine were added to the solution. To the solution was added 107 mg of dicyclohexylcarbodiimide under ice-cooling. The liquid temperature was returned to room temperature, and the mixture was stirred for 1 hour. The insoluble matter was removed by filtration, and the filtrate was washed with 1N hydrochloric acid, and dried over anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using, as eluent, 10% acetone-containing chloroform and then 3% methanol-containing chloroform to obtain 113 mg of the entitled compound as an oily substance. [α] 25 / D : +35.6° (c=1.1, chloroform) 2) Preparation of 2-(diphenylphosphonoxy)ethyl 4-O-[3-(benzyloxycarbonyl)propionyl-2-deoxy-6-O[2-deoxy-4-O-diphenylphosphono-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside In the same manner as in Example 1-2), 327 mg of the compound prepared in 1) above was treated with a zinc powder in an acetic acid solution, and the product was reacted with tetradecanoic acid to obtain 226 mg of the entitled compound as an oily substance. [α] 25 / D : +29.6° (c=1.2, chloroform) 3) Preparation of 2-phosphonoxyethyl 4-O-(3-carboxypropionyl)-2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside In the same manner as in Example 4-3), 204 mg of the compound prepared in 2) above was reacted to obtain 97 mg of the entitled compound as a white powder. Melting Point: 150-155°C (colored and jelly-like) [α] 25 / D : +24.4° (c=0.5, chloroform:methanol = 3:1 (v/v)) 3300, 2925, 2855, 1755, 1660, 1555 NMR (CDCl₃-CD₃OD), δ(ppm): 0.89 (12H, t), 1.27 (s), 2.2-2.3 (8H, m), 2.6-2.7 (4H, m), 4.18 (2H, m), 4.27 (2H, m), 4.61 (1H, d), 4.82 (1H, d), 5.06 (1H, t), 5.24 (1H, t), 5.30 (1H, t) EXAMPLES 8 TO 80 In the same manner as described in Examples 1 to 7, the following compounds represented by formula (Ia) were prepared. Physical properties of the compounds of Examples 8 to 80 are as follows. TEST EXAMPLE Fibrosarcoma cells (Meth A) (2 x 10⁵) induced in a BALB/c mouse by methyl chlolanthrene were intracutaneously implanted to the flank of seven BALB/c mice per group. A triethylamine salt of each of the compounds according to the present inventin as shown in Table 1 below was dissolved or suspended in a 0.1% (v/v) triethylamine aqueous solution to prepare a 500 µg/ml solution or suspension. The solution or suspension was administered to the mice at a dose level of 100 µg/mouse through the tail vein on the 7th, 12th, and 21st days from the implantation. The antitumor effect (%) on growth of the fibrosarcoma was determined by dividing the average tumor weight of the test group on the 21st day by the average tumor weight of the control group (non-treated group) and multiplying the quotient by 100. For comparison, the same evaluation was made by using Compound A as a comparative compound. The results obtained are shown in Table 1. Compound of Example Antitumor Effect (%) 1 19 2 13 3 5 8 9 25 11 32 24 43 7 46 8 53 6 Compound A 15 Control 100 It can be seen from Table 1 that the compounds according to the present invention exhibit antitumor activity equal or higher than Compound A. TEST EXAMPLE 2 A triethylamine salt of each of the compounds according to the present invention as shown in Table 2 below was dissolved or suspended in a 5% (w/v) glucose aqueous solution containing 0.1 (v/v) triethylamine to prepare a 100 µg/ml solution or suspension. Tne solution or suspension was administered to three NZW male rabbits per group at a dose level of 50 µg/kg-b.w. through the ear vein for consecutive three days. The toxicity was evaluated by the number of dead animals after 24 hours from the final administration/the number of test animals. For comparison, Compound A was administered at a level of 5 µg/kg-b.w. The results obtained are shown in Table 2. Compound of Example Dose Level (µg/kg) Number of Dead Rabbits/Number of Test Animals 1 50 0/3 8 50 0/3 25 50 0/3 32 50 0/3 46 50 0/3 Compound A 5 4/4 As is apparent from Table 2, the compounds according to the present invention have toxicity lower than 1/10 of that of Compound A and thus prove excellent in safety.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A compound represented by formula (I): wherein R represents ZR⁶ or wherein Z, Z¹, and Z² each represents an alkylene group having from 1 to 6 carbon atoms, and R⁶ represents a carboxyl group or a phosphonoxy group; R¹, R², R³, and R⁴ each represents -COR⁷, -COZ³R⁸, -CO(CH₂) n2 OCOR⁷, -CO(CH₂) n2 OCOZ³R⁸, -CO(CH₂) n2 COR⁷, -CO(CH₂) n2 COZ³R⁸, or wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms which may be substituted with one or more hydroxyl groups, Z³ represents an alkylene group having from 1 to 9 carbon atoms, R⁸ represents a cycloalkyl group having from 3 to 12 carbon atoms which may be substituted with one or more hydroxyl groups, Q represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, -CONH₂, -COOH or -CH₂OH, Q₁ represents a hydrogen atom or an alkyl group having from 1 to 20 carbon atoms, n1 represents 0 or an integer of from 1 to 20, and n2 and n3 each represents an integer of from 1 to 20; and R⁵ represents a hydrogen atom, a phosphono group or -CO(CH₂) m COOH, wherein m represents 0 or an integer of from 1 to 6, and the salts thereof. A compound as claimed in claim 1, wherein R represents ZR⁶ or and R¹, R², R³, and R⁴ each represents -COR⁷, -COZ³R⁸, -CO(CH₂) n2 COR⁷ or -CO(CH₂) n2 COZ³R⁸. A compound as claimed in claim 2, wherein R represents ZOPO(OH)₂; and R¹, R², R³, and R⁴ each represents -COR⁷ or A compound as claimed in claim 1 or claim 2 wherein R represents ZR⁶ wherein Z represents a methylene or an ethylene group and R⁶ represents a carboxyl group or a phosphonoxy group R¹ and R³ each represents -COR⁷ wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms R² and R⁴ each represents wherein n1 represents 0 (zero), Q and Q₁ each represent a hydrogen atom and R⁷ represents an alkyl group having from 1 to 30 carbon atoms or -COR⁷ wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms, and R⁵ represents a hydrogen atom. The compounds as claimed in claim 2, which are: 1,3-dicarboxyisopropyl 2-deoxy-6-O-[2-deoxy-3-0-(N-dodecanoylglycyl)-4-0-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-2-(N-dodecanoyl-N-methylglycylamino)-4-0-phosphono-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-(N-dodecanoyl-N-methylglycylamino)-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoylamino]-4-O-phosphono-β-D-glucopyranosyl]-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoylamino]-α-D-glucopyranoside; carboxymethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-tetradecanoyl-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosophonoxyethyl 2-deoxy-6-O-[2-deoxy-2-(6-octanoylaminohexanoylamino)-4-O-phosphono-3-O-tetradecanoyl-β-D-glucopyranosyl]-2-(6-octanoylaminohexanoyl)amino-3-O-tetradecanoyl-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-[(6-octanoylamino)-hexanoylamino]-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-tetradecanoyl-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-2-(8-hexanoylaminooctanoylamino)-3-O-tetradecanoyl-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-2-(8-hexanoyl-aminooctanoylamino)-4-O-phosphono-3-O-tetradecanoyl-β-D-glucopyranosyl]-2-(8-hexanoylaminooctanoylamino)-3-O-tetradecanoyl-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-2-(N-dodecanoyl-N-methylglycylamino)-3-O-(4-oxotetradecanoyl)-4-O-phosphono-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-(N-dodecanoyl-N-methylglycylamino)-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(4-oxotetradecanoyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-[6-N-methyl-N-octanoylamino)hexanoyl-amino]-α-D-glucopyranoside. A process for preparing the compound of the claims 1 to 5 characterized in that a compound of the general formula II wherein R⁹ represents a hydrogen atom or a hydroxyl-protective group; R¹⁰ represents ZCOOR¹⁴, ZOPO(OR¹³)₂, or R¹¹, R²¹, and R³¹ each represents -COR⁷¹, -COZ³R⁸¹, -CO(CH₂) n2 OCOR⁷¹ , -CO(CH₂) n2 OCOZ³R⁸¹, -CO(CH₂) n2 COR⁷¹, -CO(CH₂) n2 COZ³R⁸¹, R⁵¹ represents a hydrogen atom, -CO(CH₂) m COOR¹⁶ or PO(OR¹⁵)₂, wherein R¹² and R¹³ each represents a phosphonoprotective group; R¹⁴ represents a carboxyl-protective group; R⁷¹ represents an alkyl group having from 1 to 30 carbon atoms which may be substituted with one or more hydroxyl groups protected with a hydroxyl-protective group; R⁸¹ represents a cycloalkyl group having from 3 to 12 carbon atoms which may be substituted with one or more hydroxyl groups protected with a hydroxyl-protective group; Q² represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, -CONH₂, -COOR¹⁶ or -CH₂-O-R⁹¹, wherein R¹⁶ represents a carboxyl-protective group; R¹⁵ represents a phosphono-protective group; R⁹¹ represents a hydroxyl-protective group and Z, Z¹, Z², Z³, Q¹, n1, n2, n3 and m are as defined in claim 1, is catalytically reduced with hydrogen in an inert solvent and, if desired, the so obtained compound of formula I is converted to a salt thereof. The compounds of claims 1 to 5 for use in a method for treatment of the human or animal body. A pharmaceutical composition comprising at least one of the compounds of claims 1 to 5, optionally together with conventional pharmaceutically acceptable carriers and/or adjuvants. A process for preparing the pharmaceutical composition of claim 8 characterized in that at least one compound of claims 1 to 5 is provided in a suitable administration form, optionally with incorporation of a conventional carrier and/or adjuvant. Claims for the following Contracting State : ES A process for preparing the compounds represented by formula (I): wherein R represents ZR⁶ or wherein Z, Z¹, and Z² each represents an alkylene group having from 1 to 6 carbon atoms, and R⁶ represents a carboxyl group or a phosphonoxy group; R¹, R², R³, and R⁴ each represents -COR⁷, -COZ³R⁸, -CO(CH₂) n2 OCOR⁷, -CO(CH₂) n2 OCOZ³R⁸ , -CO(CH₂) n2 COR⁷, -CO(CH₂) n2 COZ³R⁸, or wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms which may be substituted with one or more hydroxyl groups, Z³ represents an alkylene group having from 1 to 9 carbon atoms, R⁸ represents a cycloalkyl group having from 3 to 12 carbon atoms which may be substituted with one or more hydroxyl groups, Q represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, -CONH₂, -COOH or -CH₂OH, Q₁ represents a hydrogen atom or an alkyl group having from 1 to 20 carbon atoms, n1 represents 0 or an integer of from 1 to 20, and n2 and n3 each represents an integer of from 1 to 20; and R⁵ represents a hydrogen atom, a phosphono group or -CO(CH₂) m COOH, wherein m represents 0 or an integer of from 1 to 6, and the salts thereof, characterized in that a compound of the general formula II wherein R⁹ represents a hydrogen atom or a hydroxyl-protective group; R¹⁰ represents ZCOOR¹⁴, ZOPO(OR¹³)₂, or R¹¹, R²¹, and R³¹ each represents -COR⁷¹, -COZ³R⁸¹, -CO(CH₂) n2 OCOR⁷¹, -CO(CH₂) n2 OCOZ³R⁸¹, -CO(CH₂) n2 COR⁷¹ , -CO(CH₂) n2 COZ³R⁸¹, R⁵¹ represents a hydrogen atom, -CO(CH₂) m COOR¹⁶ or PO(OR¹⁵)₂, wherein R¹² and R¹³ each represents a phosphono-protective group; P¹⁴ represents a carboxyl-protective group; R⁷¹ represents an alkyl group having from 1 to 30 carbon atoms which may be substituted with one or more hydroxyl groups protected with a hydroxyl-protective group; R⁸¹ represents a cycloalkyl group having from 3 to 12 carbon atoms which may be substituted with one or more hydroxyl groups protected with a hydroxyl-protective group; Q² represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, -CONH₂, -COOR¹⁶ or -CH₂-O-R⁹¹, wherein R¹⁶ represents a carboxyl-protective group; R¹⁵ represents a phosphono-protective group; R⁹¹ represents a hydroxyl-protective group and Z, Z¹, Z², Z³, Q¹, n1, n2, n3 and m are as defined above. is catalytically reduced with hydrogen in an inert solvent and, if desired, the so obtained compound of formula I is converted to a salt thereof. A process as claimed in claim 1, wherein R represents ZR⁶ or and R¹, R², R³, and R⁴ each represents -COR⁷, -COZ³R⁸, -CO(CH₂) n2 COR⁷ or -CO(CH₂) n2 COZ³R⁸. A process as claimed in claim 2, wherein R represents ZOPO(OH)₂; and R¹, R², R³, and R⁴ each represents -COR⁷ or A process as claimed in claim 1 or claim 2 wherein R represents ZR⁶ wherein Z represents a methylene or an ethylene group and R⁶ represents a carboxyl group or a phosphonoxy group R¹ and R³ each represents -COR⁷ wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms R² and R⁴ each represents wherein n1 represents 0 (zero). Q and Q₁ each represent a hydrogen atom and R⁷ represents an alkyl group having from 1 to 30 carbon atoms or -COR⁷ wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms, and R⁵ represents a hydrogen atom. A process as claimed in claim 2, wherein the following compounds are obtained: 1,3-dicarboxyisopropyl 2-deoxy-6-O-[2-deoxy-3-0-(N-dodecanoylglycyl)-4-0-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoyl-amino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-2-(N-dodecanoyl-N-methylglycylamino)-4-0-phosphono-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-(N-dodecanoyl-N-methylglycylamino)-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoylamino]-4-O-phosphono-β-D-glucopyranosyl]-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoylamino]-α-D-glucopyranoside; carboxymethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-tetradecanoyl-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosophonoxyethyl 2-deoxy-6-O-[2-deoxy-2-(6-octanoylaminohexanoylamino)-4-O-phosphono-3-O-tetradecanoyl-β-D-glucopyranosyl]-2-(6-octanoylaminohexanoyl)amino-3-O-tetradecanoyl-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-[(6-octanoylamino)-hexanoylamino]-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-tetradecanoyl-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-2-(8-hexanoylaminooctanoylamino)-3-O-tetradecanoyl-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-2-(8-hexanoylaminooctanoylamino)-4-O-phosphono-3-O-tetradecanoyl-β-D-glucopyranosyl]-2-(8-hexanoylaminooctanoylamino)-3-O-tetradecanoyl-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-2-(N-dodecanoyl-N-methylglycylamino)-3-O-(4-oxotetradecanoyl)-4-O-phosphono-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-(N-dodecanoyl-N-methylglycylamino)-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(4-oxotetradecanoyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-[6-N-methyl-N-octanoylamino)hexanoyl-amino]-α-D-glucopyranoside. A process for preparing a pharmaceutical composition characterized in that at least one compound as defined in claims 1 to 5 is provided in a suitable administration form, optionally with incorporation of a conventional carrier and/or adjuvant. Claims for the following Contracting State : GR A compound represented by formula (I): wherein R represents ZR⁶ or wherein Z, Z¹, and Z² each represents an alkylene group having from 1 to 6 carbon atoms, and R⁶ represents a carboxyl group or a phosphonoxy group; R¹, R², R³, and R⁴ each represents -COR⁷, -COZ³R⁸, -CO(CH₂) n2 OCOR⁷, -CO(CH₂) n2 OCOZ³R⁸, -CO(CH₂) n2 COR⁷, -CO(CH₂) n2 COZ³R⁸, or wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms which may be substituted with one or more hydroxyl groups, Z³ represents an alkylene group having from 1 to 9 carbon atoms, R⁸ represents a cycloalkyl group having from 3 to 12 carbon atoms which may be substituted with one or more hydroxyl groups, Q represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, -CONH₂, -COOH or -CH₂OH, Q₁ represents a hydrogen atom or an alkyl group having from 1 to 20 carbon atoms, n1 represents 0 or an integer of from 1 to 20, and n2 and n3 each represents an integer of from 1 to 20; and R⁵ represents a hydrogen atom, a phosphono group or -CO(CH₂) m COOH, wherein m represents 0 or an integer of from 1 to 6, and the salts thereof. A compound as claimed in claim 1, wherein R represents ZR⁶ or and R¹, R², R³, and R⁴ each represents -COR⁷, -COZ³R⁸, -CO(CH₂) n2 COR⁷ or -CO(CH₂) n2 COZ³R⁸. A compound as claimed in claim 2, wherein R represents ZOPO(OH)₂; and R¹, R², R³, and R⁴ each represents -COR⁷ or A compound as claimed in claim 1 or claim 2 wherein R represents ZR⁶ wherein Z represents a methylene or an ethylene group and R⁶ represents a carboxyl group or a phosphonoxy group R¹ and R³ each represents -COR⁷ wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms R² and R⁴ each represents wherein n1 represents 0 (zero). Q and Q₁ each represent a hydrogen atom and R⁷ represents an alkyl group having from 1 to 30 carbon atoms or -COR⁷ wherein R⁷ represents an alkyl group having from 1 to 30 carbon atoms, and R⁵ represents a hydrogen atom. The compounds as claimed in claim 2, which are: 1,3-dicarboxyisopropyl 2-deoxy-6-O-[2-deoxy-3-0-(N-dodecanoylglycyl)-4-0-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoyl-amino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-2-(N-dodecanoyl-N-methylglycylamino)-4-0-phosphono-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-(N-dodecanoyl-N-methylglycylamino)-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoylamino]-4-O-phosphono-β-D-glucopyranosyl]-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoylamino]-α-D-glucopyranoside; carboxymethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-tetradecanoyl-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosophonoxyethyl 2-deoxy-6-O-[2-deoxy-2-(6-octanoylaminohexanoylamino)-4-O-phosphono-3-O-tetradecanoyl-β-D-glucopyranosyl]-2-(6-octanoylaminohexanoyl)amino-3-O-tetradecanoyl-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-[(6-octanoylamino)-hexanoylamino]-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-tetradecanoyl-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-2-(8-hexanoylaminooctanoylamino)-3-O-tetradecanoyl-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-2-(8-hexanoylaminooctanoylamino)-4-O-phosphono-3-O-tetradecanoyl-β-D-glucopyranosyl]-2-(8-hexanoylaminooctanoylamino)-3-O-tetradecanoyl-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-2-(N-dodecanoyl-N-methylglycylamino)-3-O-(4-oxotetradecanoyl)-4-O-phosphonoβ-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-(N-dodecanoyl-N-methylglycylamino)-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(4-oxotetradecanoyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-tetradecanoylamino-α-D-glucopyranoside; 2-phosphonoxyethyl 2-deoxy-6-O-[2-deoxy-3-O-(N-dodecanoylglycyl)-4-O-phosphono-2-tetradecanoylamino-β-D-glucopyranosyl]-3-O-(N-dodecanoylglycyl)-2-[6-N-methyl-N-octanoylamino)hexanoyl-amino]-α-D-glucopyranoside. A process for preparing the compounds of claims 1 to 5 characterized in that a compound of the general formula II wherein R⁹ represents a hydrogen atom or a hydroxyl-protective group; R¹⁰ represents ZCOOR¹⁴, ZOPO(OR¹³)₂, or R¹¹, R²¹, and R³¹ each represents -COR⁷¹, -COZ³R⁸¹, -CO(CH₂) n2 OCOR⁷¹, -CO(CH₂) n2 OCOZ³R⁸¹, -CO(CH₂) n2 COR⁷¹, -CO(CH₂) n2 COZ³R⁸¹, R⁵¹ represents a hydrogen atom, -CO(CH₂) m COOR¹⁶ or PO(OR¹⁵)₂, wherein R¹² and R¹³ each represents a phosphono-protective group; R¹⁴ represents a carboxyl-protective group; R⁷¹ represents an alkyl group having from 1 to 30 carbon atoms which may be substituted with one or more hydroxyl groups protected with a hydroxyl-protective group; R⁸¹ represents a cycloalkyl group having from 3 to 12 carbon atoms which may be substituted with one or more hydroxyl groups protected with a hydroxyl-protective group; Q² represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, -CONH₂, -COOR¹⁶ or -CH₂-O-R⁹¹, wherein R¹⁶ represents a carboxyl-protective group; R¹⁵ represents a phosphono-protective group; R⁹¹ represents a hydroxyl-protective group and Z, Z¹, Z², Z³, Q¹, n1, n2, n3 and m are as defined in claim 1, is catalytically reduced with hydrogen in an inert solvent and, if desired, the so obtained compound of formula I is converted to a salt thereof. The compounds of claims 1 to 5 for use in a method for treatment of the human or animal body. A process for preparing a pharmaceutical composition characterized in that at least one compound of claims 1 to 5 is provided in a suitable administration form, optionally with incorporation of a conventional carrier and/or adjuvant.

Inventors: KUSAMA, TSUNEO C/O DAIICHI SEIYAKU, SHIBA, TETSUO, SOGA, TSUNEHIKO C/O DAIICHI SEIYAKU
Applicants: DAIICHI PHARMACEUTICAL CO., LTD.
Application year: 1988
Main classification: C07H13
IPC codes: A61K31, C07H15, C07H13